Trials / Completed
CompletedNCT06191991
A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)
A Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Aligos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs). In Parts 1 and 2, the drug-drug interaction (DDI) potential of ALG-055009 will be explored, where subjects will be assigned to receive multiple doses of ALG-055009 and 2 single doses of one of the following concomitant drugs: atorvastatin (Part 1), or rosuvastatin (Part 2, optional).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin | 40 mg |
| DRUG | ALG-055009 | 0.9 mg |
| DRUG | Rosuvastatin | 10 mg |
Timeline
- Start date
- 2023-11-03
- Primary completion
- 2023-11-27
- Completion
- 2023-12-04
- First posted
- 2024-01-05
- Last updated
- 2025-02-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06191991. Inclusion in this directory is not an endorsement.